Lupin share price fell nearly 2 percent in the early trade on February 11 despite the company received United States Food and Drug Administration (USFDA) approval for nasal spray.
At 09:23am, Lupin was quoting at Rs 2,133.30, down Rs 36.55, or 1.68 percent, on the BSE.
The USFDA approved company’s Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% (21 mcg/spray), to market a generic equivalent of Atrovent Nasal Spray, 0.03%, of Boehringer Ingelheim Pharmaceuticals, Inc.
The product will be manufactured at Lupin’s Pithampur facility in India.
Ipratropium Bromide Nasal Solution id use for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.
Catch all the market action on our live blog
Earlier on February 10, the company with its alliance partner Natco Pharma received an approval from the USFDA for Natco’s ANDA for Bosentan tablets for oral suspension, 32 mg, to market a generic equivalent of Tracleer Tablets for Oral Suspension of Actelion Pharmaceuticals US, Inc.
Natco is the exclusive first-to-file for this product and is eligible for 180 days exclusivity.
A meeting of the board of directors of the company is scheduled to be held on February 11, 2025,
to consider and approve the unaudited standalone and consolidated financial results of the
company for the quarter and nine months ended December 31, 2024.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
